This report contains 537 pages, 42 tables, and presents a comprehensive analysis of the Japanese hospital tumor marker testing market, including:
- Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
- Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
- Test volume and sales forecasts for 40 tumor markers & performed in Japanese hospitals.
- Current instrumentation technologies and feature comparison of leading analyzers.
- Sales and market shares of & leading suppliers.
- Emerging diagnostic technologies and their potential market applications.
- Product development opportunities.
- Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
- Business opportunities and strategic recommendations for suppliers.
Companies Mentioned
- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- GSK Biologicals
- Hologic
- Leica Biosystems
- Lonza
- Ortho-Clinical Diagnostics
- PerkinElmer
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens Healthineers
- Takara Bio
- Thermo Fisher
- Wako
